


# Accepted Manuscript



Long-term anticoagulation with rivaroxaban for preventing recurrent VTE: A benefit-risk analysis of EINSTEIN EXTENSION

Philip S. Wells, MD, Martin H. Prins, MD, PhD, Bennett Levitan, MD, PhD, Jan Beyer-Westendorf, MD, Timothy A. Brighton, MD, Henri Bounameaux, MD, Alexander T. Cohen, MD, FRACP, Bruce L. Davidson, MD, MPH, Paolo Prandoni, MD, PhD, Gary E. Raskob, PhD, Zhong Yuan, MD, PhD, Eva G. Katz, PhD, MPH, Martin Gebel, PhD, Anthonie WA. Lensing, MD, PhD

PII: S0012-3692(16)49110-5

DOI: [10.1016/j.chest.2016.05.023](https://doi.org/10.1016/j.chest.2016.05.023)

Reference: CHEST 492

To appear in: *CHEST*

Received Date: 11 January 2016

Revised Date: 4 April 2016

Accepted Date: 23 May 2016

Please cite this article as: Wells PS, Prins MH, Levitan B, Beyer-Westendorf J, Brighton TA, Bounameaux H, Cohen AT, Davidson BL, Prandoni P, Raskob GE, Yuan Z, Katz EG, Gebel M, Lensing AW, Long-term anticoagulation with rivaroxaban for preventing recurrent VTE: A benefit-risk analysis of EINSTEIN EXTENSION, *CHEST* (2016), doi: [10.1016/j.chest.2016.05.023](https://doi.org/10.1016/j.chest.2016.05.023).

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# Long-term anticoagulation with rivaroxaban for preventing recurrent VTE: A benefit–risk analysis of EINSTEIN EXTENSION

Philip S Wells, MD<sup>1</sup>, Martin H Prins, MD, PhD<sup>2</sup>, Bennett Levitan, MD, PhD<sup>3</sup>, Jan Beyer-Westendorf, MD<sup>4</sup>, Timothy A Brighton, MD<sup>5</sup>, Henri Bounameaux, MD<sup>6</sup>, Alexander T Cohen, MD, FRACP<sup>7</sup>, Bruce L Davidson, MD, MPH<sup>8</sup>, Paolo Prandoni, MD, PhD<sup>9</sup>, Gary E Raskob, PhD<sup>10</sup>, Zhong Yuan, MD, PhD<sup>3</sup>, Eva G Katz, PhD, MPH<sup>11</sup>, Martin Gebel, PhD<sup>12</sup>, and Anthonie WA Lensing, MD, PhD<sup>12</sup>

1. Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ontario, Canada
2. Maastricht University Medical Center, Maastricht, The Netherlands
3. Janssen Pharmaceutical Research & Development LLC, Titusville, NJ, United States
4. University Hospital “Carl-Gustav Carus”, Department of Vascular Medicine, Technische Universität Dresden, Germany
5. Department of Haematology, Prince of Wales Hospital, Sydney, New South Wales, Australia
6. Division of Angiology and Hemostasis, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland
7. Department of Haematological Medicine, Guys and St Thomas’ Hospitals, King’s College Hospital, London, UK
8. University of Washington School of Medicine, Seattle, WA, USA
9. Department of Cardiovascular Sciences, University of Padua, Padua, Italy
10. University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City, OK, USA
11. Janssen Pharmaceutical Research & Development LLC, Raritan, NJ, United States
12. Bayer HealthCare AG, Wuppertal, Germany

## Corresponding author:

Name: Philip S Wells

Address: Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ontario, Canada

Email: pwells@toh.on.ca

Download English Version:

<https://daneshyari.com/en/article/5600619>

Download Persian Version:

<https://daneshyari.com/article/5600619>

[Daneshyari.com](https://daneshyari.com)